Skip to content
DataLookout
Menu

NCT07646145

Disitamab Vedotin Plus Intravesical Mitomycin C in HER2-Expressing Intermediate- to High-Risk Non-Muscle-Invasive Bladder Cancer

StatusRecruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Enrollment increased: 30 → 50 participants
    • Eligibility criteria expanded, about 21 words
    • Secondary endpoints: details revised at 2 of 3 entries
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

1-year disease-free survival rate(1-year DFS rate)
Timeframe: At 12 months after the first study treatment.

Secondary (3)

Disease-free survival
Overall Survival(OS)
Incidence and Severity of Treatment-emergent Adverse Events

Arms and interventions

Disitamab Vedotin Plus Intravesical Mitomycin CExperimental

Participants will receive intravenous disitamab vedotin in combination with intravesical mitomycin C according to the protocol-defined treatment schedule.

Drugs: Disitamab Vedotin, Mitomycin C (MMC)

Sites

1 site in 1 country

  • Shanxi Provincial Cancer HospitalTaiyuan, Shanxi, China